<DOC>
	<DOCNO>NCT00735696</DOCNO>
	<brief_summary>The purpose study evaluate progression-free survival ( PFS ) rate 6 month ramucirumab administer combination paclitaxel carboplatin first-line therapy Stage IIIB IV non-small cell lung cancer</brief_summary>
	<brief_title>A Study Ramucirumab ( IMC-1121B ) With Paclitaxel Carboplatin Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Non-small cell lung cancer ( NSCLC ) account 75-80 % lung cancer . The advanced stage associate poor survival rate , median survival rate approximately 3.9 month leave untreated . Angiogenesis process wound heal restore blood flow tissue injury . It physiological process involve growth new blood vessel pre-existing vessel . Angiogenesis may promote growth factor diseases cancer , growth factor express , body lose ability maintain balance angiogenesis . This may embellish exist supply blood ; potentially increase delivery oxygen nutrient supply cancer growth survival . Ramucirumab angiogenesis inhibitor ; believe block promotion growth factor form new blood vessel , thus reduce blood supply cancer cell .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically cytologically confirm NSCLC Advanced NSCLC Measurable disease ( define Response Evaluation Criteria Solid Tumors [ RECIST 1.0 ] ) Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 1 Age ≥ 18 year Adequate hematologic function = absolute neutrophil count ( ANC ) ≥ 1500/μL , hemoglobin ≥ 9 g/dL , platelet count ≥ 100,000/microliter ( μL ) Adequate hepatic function = total bilirubin ≤ 1.5 mg/dL transaminase alkaline phosphatase ≤ 5 x upper limit normal ( ULN ) Adequate renal function serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ( CrCl ) &gt; 60 mL/minute , urine dipstick protein &lt; 1+ ( ie , either 0 trace ) Adequate coagulation function , INR ≤ 1.5 partial thromboplastin time ( PTT ) ≤ 5 second ULN Adequate contraception Signed informed consent Untreated CNS metastasis Prior bevacizumab therapy Radiologically document evidence major blood vessel invasion encasement cancer Prior systemic chemotherapy Stage IIIB/IV NSCLC Prior systemic chemotherapy radiation therapy Stage IIIIA NSCLC &lt; 1 year prior Any concurrent malignancy basal cell skin cancer , carcinoma situ cervix Concurrent treatment anticancer therapy , include chemotherapy , immunotherapy , hormonal therapy , radiotherapy , chemoembolization , target therapy Ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Uncontrolled thrombotic hemorrhagic disorder Poorlycontrolled hypertension Chronic daily treatment aspirin ( &gt; 325 mg/day ) know inhibitor platelet function History gross hemoptysis ( define bright red blood ≥ 1/2 teaspoon ) Serious nonhealing wound , ulcer , bone fracture Undergone major surgery subcutaneous venous access device placement . Postoperative bleeding complication wind complication surgical procedure perform last 2 month Elective plan major surgery perform course trial Peripheral neuropathy ≥ Grade 2 ( National Cancer Institute Common Toxicity Criteria Adverse Events , Version 3.0 [ NCICTCAE v 3.0 ] ) If female , pregnant lactate Radiographic evidence intratumor cavitation Grade 34 gastrointestinal bleeding within 3 month prior study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Lung</keyword>
	<keyword>NSCLC</keyword>
</DOC>